High-risk BLCA patients showed better efficacy against Cisplatin, Ribociclib, SB216763, and Obatoclax Mesylate, Venetoclax, and higher resistance to Cytarabine, Lapatinib, Linsitinib, Nilotinib, MK-2206 (AKT inhibitor), Rapamycin (mTOR inhibitor), and Navitoclax. This evidence concerns the gene MTOR and bladder transitional cell carcinoma.